Angiotensin receptor/neprilysin inhibitor —a breakthrough in chronic heart failure therapy: summary of subanalysis on PARADIGM-HF trial findings

This article includes also recently announced findings on the TRANSITION study which revealed that HFrEF therapy with ARNI might be safely initiated after an acute decompensated heart failure episode, including patients with heart failure de novo and ACEI/ARB na ïve, both hospitalised or shortly after discharge, in contrary to the PARADIGM-HF trial, where patients had to be administered a stable dose of an ACEI/ARB equivalent to enalapril 10 mg a day for at least 4 weeks before the screening.
Source: Heart Failure Reviews - Category: Cardiology Source Type: research